It is obviously desirable to investigate the prognostic value of WT1 in each subtype individually rather than treating ovarian cancer as a homogeneous malignancy; however, since it is not feasible at present to secure the specific data regarding WT1 expression status and patients' survival data in each ovarian cancer subtype, we were unable to do this potentially important individualized analysis. This evidence concerns the gene WT1 and ovarian cancer.